ORMP oramed.com: Rasio rega marang prakiraan pendapatan
Oramed Pharmaceuticals is implementing innovative capsules for injection-free insulin administration, ensuring sustainable demand. Its Israeli origin and humanitarian status minimize geopolitical threats. The forward P/S trend visualizes market expectations, where the current parameter equals 84.30. Moving away from needles in favor of oral forms radically reduces medical waste, supporting ESG principles.
ORMP (oramed.com): rincian analitis lan laporan miturut indikator
- rega pasar lan target rega analis:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal Oramed Pharmaceuticals|ORMP - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal Oramed Pharmaceuticals Inc.|ORMP - Utang agregat perusahaan|Utang marang nilai buku ORMP|ORMP - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Oramed Pharmaceuticals|Rasio cepet oramed.com
- rincian asil keuangan lan kelipatan valuasi:
ORMP - Bathi pungkasan|Proyeksi bathi mangsa ngarep Oramed Pharmaceuticals|ORMP - Pangali P/E|Rega marang bathi mangsa ngarep Oramed Pharmaceuticals Inc.|ORMP - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan ORMP|ORMP - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Oramed Pharmaceuticals|ORMP - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan oramed.com|ORMP - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Oramed Pharmaceuticals
- data total pendapatan lan volume dodolan:
Pambiji fundamental perusahaan:Oramed Pharma (ORMP)
Reliable distribution and strict supply chain control of oral insulin at Oramed Pharmaceuticals (ORMP) create the foundation for projected sales growth. Reflecting the ratio of market capitalization to expected revenue for the coming year, the forward price-to-sales valuation trend allows investors to assess the premium for future business expansion rates and identify risks of multiple compression in a timely manner.
Pesaing wigati
Rasio rega marang prakiraan pendapatan Haleon HLN|Kenvue Inc (KVUE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|VRNA - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan MENS (Jyong Bio)|LGND: Multiplikator Forward P/S|amneal.com (AMRX) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Perrigo|Multiplikator forward rega marang pendapatan Alvotech S.A. (ALVO)|Multiplikator Forward P/S LQDA|GLPG - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S ANIP (ANI Pharmaceuticals)|MNKD: Kapitalisasi marang prakiraan pendapatan|AMPH: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan PCRX (Pacira Pharmaceuticals)|ARS Pharma (SPRY) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TBPH (Theravance Corp)|AQST (Aquestive Therapeutics) - Multiplikator Forward P/S|SCPH: Rega forward marang dodolan|Multiplikator Forward P/S TECX|Multiplikator Forward P/S Tonix Pharma (TNXP)|Rasio rega marang prakiraan pendapatan China SXT Pharmaceuticals, Inc. SXTC|Rega forward marang dodolan EPRX|BHST - Rasio rega marang prakiraan pendapatan|invizyne.com (EXOZ) - Multiplikator forward rega marang pendapatan|ENTX: Multiplikator Forward P/S|MindWalk Holdings, Inc. (HYFT) - Multiplikator Forward P/S|ABVC (ABVC BioPharma Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Cumberland Corp (CPIX)|Multiplikator Forward P/S QNTM|FGEN - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Telomir Pharmaceuticals, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Rani Therapeutics Holdings RANI|SNYR: Multiplikator forward rega marang pendapatan|Rallybio Corporation - Rasio rega marang pendapatan sing dikarepake|LEXX: Multiplikator Forward P/S|PULM - Rasio kapitalisasi marang dodolan sing dikarepake|PTHL (Pheton Holdings Limited) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Aptorum (APM)|Multiplikator Forward P/S LYRA|Multiplikator Forward P/S Impact BioMedical, Inc. (IBO)|Rasio rega marang prakiraan pendapatan TNF Pharmaceuticals, Inc. TNFA|cbdMD Inc. - Rasio rega marang prakiraan pendapatan|PRFX - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Altamira Therapeutics CYTO|Lipella (LIPO) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OptiNose Corp (OPTN)|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals|PROC: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Petros Pharmaceuticals, Inc. (PTPI)|Multiplikator forward rega marang pendapatan Qilian International Holding Group QLI|Rasio rega marang prakiraan pendapatan ACELYRIN, Inc. SLRN|TFFP (TFF Pharmaceuticals, Inc) - Rega mangsa ngarep marang pendapatan
